Argenx announces approval of vyvdura® (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in japan for generalized myasthenia gravis

Availability of vyvgart ® and self-administered vyvdura demonstrates continued commitment to providing more choice and flexibility for gmg patients in japan jan. 18, 2024, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that japan's ministry of health, labour and welfare (mhlw) approved vyvdura® (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous (sc) use for the treatment of adult patients with generalized myasthenia gravis (gmg), who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ists). following this decision, vyvgart is now approved in japan for both intravenous (iv) and self-administered sc use.
ARGX Ratings Summary
ARGX Quant Ranking